Zai Lab Announces Updated Phase 1 Data for DLL3-Targeted ADC Zocilurtatug Pelitecan in Small Cell Lung Cancer at 2025 AACR-NCI-EORTC Conference
Reuters
Oct 14, 2025
<a href="https://laohu8.com/S/ZAILF">Zai Lab</a> Announces Updated Phase 1 Data for DLL3-Targeted ADC Zocilurtatug Pelitecan in Small Cell Lung Cancer at 2025 AACR-NCI-EORTC Conference
Zai Lab Ltd. has announced that updated data from its global Phase 1 clinical trial evaluating zocilurtatug pelitecan (zoci), formerly known as ZL-1310, will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 22-26, 2025, in Boston, Massachusetts. The oral presentation will include additional follow-up from patients in the ongoing trial. Zoci is a Delta-like ligand (DLL3)-targeted antibody-drug conjugate $(ADC)$ being developed for patients with previously treated extensive-stage small cell lung cancer (ES-SCLC). Zai Lab plans to initiate a Phase 3 registrational study in this patient population by the end of the year. The company will also host an investor conference call and webcast to discuss the updated trial data and clinical development plans on October 24, 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zai Lab Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251013594159) on October 13, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.